MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell malignancies, we prepared MUM1-expressing Ba/F3 cells, which proliferated until higher cellular density than the parental cells, and performed cDNA microarray analysis to identify genes whose expression is regulated by MUM1. We found that the expression of four genes including FK506-binding protein 3 (FKBP3), the monokine induced by interferonc(MIG), Fas apoptotic inhibitory molecule (Faim) and Zinc-finger protein 94 was altered in the MUM1-expressing cells. We then focused on MIG since its expression was immediately upregulated by MUM1. In reporter assays, MUM1 activated the MIG promoter in cooperation with PU.1, and the interaction between MUM1 and the MIG promoter sequence was confirmed. The expression of MIG was correlated with that of MUM1 in B-CLL cell lines, and treatment with neutralizing antibodies against MIG and its receptor, CXCR3, slightly inhibited the proliferation of two MUM1-expressing lines. These results suggest that MUM1 plays roles in the progression of B-cell lymphoma/ leukemia by regulating the expression of various genes including MIG.
Introduction
The MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) gene was identified as a myeloma-associated proto-oncogene that was activated at the transcriptional level as a result of t(6;14)(p25;q32) chromosomal translocation.
1,2 Its expression is restricted to cells in the B-cell lineage and in activated T cells. [3] [4] [5] MUM1-deficient mice show defects principally in lymphocyte activation and in terminal B-cell differentiation toward plasma cells producing immunoglobulins (Ig). 6 MUM1 is a member of the IRF family and functions as a transcription regulatory factor. 4, 5, 7, 8 MUM1 has a DNA-binding domain at its amino-terminus and binds to promoter elements that contain IFN-g-activating sequence (GAS) or IFN-stimulated response elements (ISRE). 8 MUM1 interacts with various transcription factors, such as IRF1/IRF2 and Ets family member, PU.1, and can function as either a transcriptional activator or repressor of its target genes. 8 Previous studies have reported that the MUM1/PU.1 complex regulated the expression of B-cellspecific genes such as Igk, Igl light chains, CD20 and CD23. [8] [9] [10] [11] MUM1-positive cells in reactive lymph nodes consist of plasma cells and a small fraction (7.9%) of B cells harboring CD20 þ 38 þ , which are localized in the light zone of the germinal center. 12 Its expression in resting B cells is also induced by mitogenic stimuli. As for B-cell lymphomas, MUM1 expression was observed in a proportion of diffuse large B-cell lymphomas (DLBCLs), marginal zone lymphomas (MZLs) and B-cell chronic lymphocytic leukemias (B-CLL)/small lymphocytic lymphomas (SLL) by immunohistochemistry. 12 The MUM1 expression in these malignancies may reflect their derivations or activated state of the B cells, as the majority of the MUM1 þ tumors do not carry chromosomal rearrangement at 6p25 locus. Also, MUM1 is highly expressed in classical Hodgkin's lymphoma and in various types of T-cell lymphomas including adult T cell leukemia and anaplastic large-cell lymphoma. 12, 13 Moreover, recently Genechip analysis demonstrated that MUM1 is preferentially clustered within the gene expression profile exhibited by activated B-cell(ABC)-like DLBCL, a subset of DLBCL associated with an unfavorable prognosis. 14 Other investigators have also found that MUM1 expression in DLBCL as detected by immunohistochemistry was associated with significantly worse survival. 15 We previously studied MUM1 expression in a series of 29 Japanese B-CLL/SLL samples and found that MUM1 expression was an independent poor prognostic factor, 16 although our results contradict another report. 17 These observations suggest that MUM1 may play certain roles in the progression of B-cell lymphoma/leukemia. In this report, we prepared Ba/F3 cells that constitutively expressed MUM1 and explored downstream genes whose expression is regulated by MUM1 by performing cDNA microarray screening.
Materials and methods

B-cell lines, establishment of stable transfectants and evaluation of their growth curves
Murine interleukin-3 (IL-3)-dependent pro-B cell line, Ba/F3, was cultured in RPMI medium containing 10% FBS and 10% culture supernatant of WEHI cells as a source of IL-3. 18 Human Burkitt lymphoma cell line, P3HR1 and four B-CLL-derived cell lines (WSU-CLL, WaC3 CD5 þ , MO1043, and MEC2) were cultured in RPMI medium containing 10% FBS. 12, 16 MEC2 cells were established from peripheral blood of the prolymphocytic transformation of the B-CLL patients. MO1043 and WSU-CLL cells were also established from peripheral blood of the advanced B-CLL patients. WaC3 CD5 þ cells were artificially immortalized by Epstein-Barr virus (EBV) infection and various cytokines ex vivo. The full-length cDNA encoding MUM1 was ligated into the pCI-neo expression vector (Promega, Madison, WI, USA). In all, 5 Â 10 6 Ba/F3 cells in 400 ml plain RPMI medium were transfected by electroporation at 0.3 kV and 960 mF using a Bio-Rad Gene Pulser (Bio-Rad Laboratories, Hercules, CA, USA) with pCI-neo or pCI-neo-MUM1 constructs and the resistant clones against 1000 mg/ml G418 were isolated.
18 MUM1 expression was detected by immunoblotting using anti-MUM1 goat serum (M-17: Santa Cruz Biotechnology, Santa Cruz, CA, USA). 12 The antisense MUM1 cDNA encompassing its full coding sequences was ligated into the pHebo-SVhygro expression vector. Transfection into the MUM1-expressing Ba/F3 cells was similarly performed and the resistant clones against 200 mg/ml hygromycin were isolated. Viable cell numbers were counted by either the trypan blue exclusion or the MTT assay. 18 Various neutralizing antibodies such as antihuman MIG monoclonal antibody (mAb) and anti-human CXCR3 mAb were purchased from R&D systems, Inc., Minneapolis, MN, USA. Stable Ba/F3 and P3HR-1 cell transfectants harboring either pMEP4b or pMEP4b-MUM1, in which the metallothionine promoter induces transient MUM1 expression, were also established by electroporation followed by selection in 200 or 900 mg/ml hygromycin, respectively. cDNA microarray analysis USA). Probes were synthesized using the Atlas Glass Fluorescent Labeling Kit (Clontech Inc.) and the synthesized probes were used for hybridization and detection on Atlas Mouse Glass Arrays 1.0 and 3.8 (Clontech Inc., http://www.bdbiosciences. com/clontech/atlas/genelists/ index. shtml). The same experiment was repeated twice. Among the 4800 genes, genes whose expression was more than 2.5 times higher or 1/4 times lower in MUM1-expressing Ba/F3 cells when compared to MUM1-negative Ba/F3 cells were considered chosen for the further analyses to confirm by Northern blot analysis. The membranes were analyzed with the aid of the software AtlasImage 1.5.
Northern blot analysis and real-time reverse transcription polymerase chain reaction (RT-PCR)
Total RNA extraction and Northern blot analysis were performed as previously described.
1,2 Quantitative RT-PCR was performed using FastStart DNA master SYBR Green I (Roche Molecular Biochemicals, Mannheim, Germany) with the aid of a LightCycler Quick System 330 (Roche Molecular Biochemicals) as previously described. 2 The primer sets for the human MIG and b-actin genes were purchased from Roche Molecular Biochemicals.
Transient transfections and reporter gene assays
The luciferase reporter construct containing the murine MIG gene 5 0 promoter (Mig-328: GenBank accession number X58682) was kindly provided by Dr Ohmori (School of Dentistry, Meikai University, Saitama, Japan). 19 Deleted mutant constructs were generated by PCR, subcloned into pGL2-Basic vector (Promega) and sequenced. The primers used for PCR are listed below. Deletion 1 (À189):
0 -cggacttcactccaacaca-3 0 . Equimolar amounts (10 mg) of wild-type or mutant reporter plasmid were transiently transfected into Ba/F3 cells, together with 10 mg pCI-neo-MUM1 and 1 mg pRL-TK (Promega) as a control for transfection efficiency. Transient transfection into 1 Â 10 5 293 cells was performed using Fugene reagents (Roche Molecular Biochemicals), 20 ng of the MIG reporter plasmid and expression construct (pCI-neo-MUM1, pCI-neo and pCMVtag2A-PU.1) together with 10ng of pRL-TK vector. pCMVtag2A-PU.1 was a gift from Dr Oikawa (Sasaki Institute, Tokyo, Japan). 20 Luciferase activity was measured at 48 h after transfection with the DualLuciferase Reporter Assay Kit (Promega). Human recombinant TNF-a and IFN-g were purchased from R&D Systems.
Chromatin immunoprecipitation assay
The Chromatin immunoprecipitation assay (ChIP) assay was performed from 1 Â 10 6 stably MUM1-transfected Ba/F3 cells fixed with 1% formaldehyde at 371C for 15 min. 21 After crosslinking, cells were immunoprecipitated overnight at 41C with 2 mg anti-MUM1(M-17) or anti-PU.1(D-19) polyclonal antibody (Santa Cruz Biotechnology). In each experiment, one sample with no antibody and one sample with an irrelevant antibody (anti-IgG) were included. Immune complexes were recovered by adding 60 ml of blocked salmon sperm DNA/ Protein A agarose beads (50% slurry; Upstate Biotechnology, Lake Placid, NY, USA). After extensive washing, the recovered Upregulation of MIG by MUM1 M Uranishi et al cross-linked DNA was purified, and resuspended in 30 ml of 10 mM Tris, 0.1 mM EDTA, pH 7.4. Fragments containing the MUM1 binding sites were detected by PCR using 2 ml of the above DNA as a template and the primer pair, 5 0 -tccacatccaggtagcaac-3 0 and 5 0 -gcatgttcttggggatcata-3 0 . PCR products were analyzed by 2% agarose gel electrophoresis. Flow cytometric analysis of CXCR3 and enzyme-linked immunosorbent assay (ELISA) for MIG Flow cytometric analysis was performed using biotinconjugated anti-CXCR3 mAb (BD PharMingen, San Diego, CA, USA). 22 Enzyme-linked immunosorbent assay (ELISA) for MIG in the culture supernatant was performed using the Human MIG Immunoassay Kit (R&D Systems, Inc.).
Results
MUM1 expression tends to promote proliferation of Ba/F3 cells MUM1 protein expression was detected in neither the parental Ba/F3 cells nor Ba/F3-pCI-neo clones, whereas it was detected in three stably transfected Ba/F3-pCI-neo-MUM1 clones (Figure 1a) . In the presence of IL-3, MUM1-expressing cells proliferated to higher cellular density at day 3 than the control cells (empty vector-transfected), although all of the clones went dying at 4 days after culture. Cotransfection of the antisense MUM1 cDNA led to the diminished MUM1 expression, which resulted in a little bit slower proliferation in MUM1-expressing Ba/F3 cells (Figure 1b) . Since the parental Ba/F3 cells were dependent on IL-3, the cellular viability was analyzed in the absence of IL-3 in the culture medium. However, no antiapoptotic effect by MUM1 expression was found in this system (data not shown).
cDNA microarray analysis of Ba/F3 cells to search for genes whose expression is regulated by MUM1/IRF4
The cDNA microarray analysis was performed to identify genes whose expression is regulated by MUM1, using cDNA probes generated from total RNA that had been extracted from MUM1-expressing and non-expressing Ba/F3 cells. Among the 4800 genes analyzed, the expression of 47 genes was significantly altered by MUM1 expression. Among them, the expression levels of four genes significantly differed between the MUM1-expressing and -nonexpressing cells in Northern blot analyses. They included three genes whose expression was upregulated in the MUM1-expressing cells, that is, FK506 binding protein 3 (FKBP3), MIG and Fas apoptotic inhibitory molecule (Faim), and one gene whose expression was downregulated in the MUM1-expressing cells, that is, Zinc-finger protein 94 (Zfp94) (Figure 2a ).
MUM1 induces upregulation of MIG and FKBP3 mRNA
Next, we examined the changes in MIG and FKBP3 mRNA expression over time in Ba/F3 cells stably transfected with an inducible MUM1 construct (pMEP4b-MUM1) or with an empty vector (pMEP4b) as a control. Stably transfected cells were analyzed for mRNA expression at different time points after the addition of 5 mM CdCl2 to the culture medium. In this system, MUM1 mRNA became detectable at 1 h and its peak level was seen at approximately 6-9 h (Figure 2b ). The amount of FKBP3 mRNA increased at 9-12 h. MIG mRNA appeared at 1 h and its peak level was seen at 9 h. CdCl2 did not induce FKBP3 nor MIG mRNA expression in control Ba/F3-pMEP4b cells (data not shown). Next, we focused on the MIG gene as its expression level over time changed in a parallel manner with that of MUM1. To confirm whether MUM1 also induces MIG mRNA expression in a human B-cell line, we established the MUM1-inducible system using the P3HR-1 cell line, which was negative for MUM1 expression. MIG together with MUM1 mRNA was quantified by quantification/RT-PCR analysis. As shown in Figure 2c , although MUM1 and MIG mRNA were not detected in parental P3HR-1 nor in P3HR-1-pMEP4b cells, MIG transcripts could be detected at 6 h in P3HR-1-pMEP4b-MUM1 cells, when the level of MUM1 mRNA was up to 12 times higher than that at 0 h. On the other hand, expression level of the CXCR3 mRNA, which encodes for the specific receptor for MIG, was not influenced by the forced expression of MUM1.
MUM1 activates the MIG promoter in cooperation with PU.1
The murine MIG gene promoter (X58682) was analyzed for possible MUM1 binding sites by using Genetyx-MAC Ver. 11.0 software (Genetyx Co., Tokyo, Japan), and four potential sites (GAS and Ets (ETS consensus sequence)/ISRE) were identified within the 5 0 promoter sequence (Figure 3a) . Ba/F3 cells endogenously expressed PU.1, IRF1 and IRF2 (data not shown). Transient expression of reporter plasmids containing the 5 0 MIG promoter (MIG-328) together with the MUM1 cDNA expression vector in Ba/F3 cells revealed that MUM1 increased its promoter activity. To determine which region was crucial for MUM1-induced promoter activity, Ba/F3 cells were transiently transfected with deleted mutant reporter plasmids together with the MUM1 expression vector, and luciferase activity was measured (Figure 3b ). Transient transfection of the deleted mutant reporter plasmids of Deletion 3 or 4 resulted in reduced promoter activity by MUM1, whereas transient transfection of other deleted mutants of Deletions 1 and 2 showed increased promoter activity. The Deletion 2 mutant reporter plasmid showed the highest luciferase activity, indicating that the region of À172 to À150 bp is important for MUM1-mediated activation of the MIG promoter. This region includes the first Ets/ISRE site (Ets/ISRE1). Since the Ets/ISRE site has been shown for MUM1 to interact with PU.1 in murine Igk and l light chain gene enhancers, 5, 10 the luciferase assay was performed using 293 cells, which express neither endogenous MUM nor PU.1 (Figure 3c ). As expected, MIG promoter activity was increased only when the cells were co-transfected with both the MUM1 and PU.1 expression constructs. On the other hand, no increased reporter activity was observed in cells that had been transfected with either MUM1 or PU.1 alone. These observations indicated that MUM1 could activate MIG promoter activity in cooperation with PU.1. To confirm that both MUM1 and PU.1 can bind to the 5 0 MIG promoter in vivo, we performed the ChIP assay using anti-MUM1 and anti-PU.1 polyclonal antibodies in MUM1-expressing Ba/F3 cells. As shown in Figure 3d , both MUM1 and PU.1 can specifically bind to the 5 0 MIG promoter, whereas no PCR product was amplified upon immunoprecipitation by an irrelevant antibody (IgG). Moreover, IFN-g and TNF-a have been demonstrated to positively regulate the transcription of MIG gene. 23, 24 As shown in Figure 3e , although IFN-g had no effect, TNF-a increased the MIG promoter activity in 293 cells when expression constructs of MUM1 and PU.1 were cotransfected.
MUM1, MIG and CXCR3 expression in human B-CLL cell lines
Next, we examined the relationship between MUM1 and MIG protein expression in four human B-CLL cell lines, as approximately 50% of B-CLL cells were reported to express MUM1. 12, 16 We also examined the expression of the MIG receptor, CXCR3 protein in these cells. Interestingly, both MIG in the culture supernatant and CXCR3 protein on the surface of B-CLL cells were observed in two out of the four cell lines, MEC2 and MO1043. These cells were also positive for MUM1 expression by immunoblot analysis. However, the two other B-CLL cell lines, WSU-CLL and WAC3, showed negative results on all three analyses (Figures 4a-c) .
Neutralizing anti-CXCR3 mAb inhibits the proliferation of MUM1-positive B-CLL cells
We next examined whether MIG and CXCR3 play a role in the proliferation of B-CLL cell lines by incubating the cells with neutralizing anti-MIG or anti-CXCR3 mAbs (Figure 4d ). Treatment with neutralizing anti-CXCR3 mAb inhibited the proliferation of MEC2 cells when compared with that upon treatment with a control IgG mAb that belonged to the same subclass. However, treatment with anti-CXCR3 mAb did not inhibit the proliferation of WSU-CLL cells, which was negative for MIG and CXCR3 expression. However, anti-MIG mAb did not inhibit the growth of MEC2 cells. It was explained by that MEC2 cells strongly expressed another CXCR3 ligand, CXCL10/IP-10 ( Figure 4e) . 25 In MO1043 cells that weakly expressed MIG and CXCR3, the growth inhibitory effect caused by anti-MIG or anti-CXCR3 mAbs was present although it was subtle. However, in Ba/F3 cells expressing MUM1, MIG played nothing in terms of their proliferation as they did not express CXCR3 on the cell surface (data not shown).
Discussion
Since the precise role of MUM1 expression in B-cell lymphoma/ leukemia had remained unknown, we investigated its roles and genes that were transcriptionally regulated by MUM1 in the B cells. Our first observation was that MUM1 expression slightly accelerated the cellular proliferation of Ba/F3 cells. An advantage in proliferation conferred by MUM1 has been also observed in fibroblast-derived cell lines.
1,26 Next, we identified four genes whose expression is regulated by MUM1, that is, MIG, FKBP3, Faim and Zfp94. In particular, FKBP3 and MIG gene expression were upregulated in Ba/F3 cells just after induction of MUM1. These results suggested that the FKBP3 and MIG gene are direct targets that are transcriptionally regulated by MUM1. FKBP3 (FKBP-25) is a member of FK506-binding proteins (FKBPs), which harbor cis-trans-isomerase (PPIase) activity.
27 FK506 binding protein 52 (FKBP52) is also a member of FKBPs and was previously reported to inhibit the DNA binding ability and transactivation function of MUM1 by post-translational modification of MUM1. 28 Therefore, FKBP3 may have a similar function as FKBP52 on MUM1 in B cells and MUM1 may be able to transactivate the repressor proteins, which inhibit its own function by a negative feedback mechanism.
In this study, we focused on the MIG gene and performed promoter analyses, which resulted in the finding that the À172 to À150 bp region in the 5 0 MIG promoter was important for activation by MUM1. This region contained a potential Ets/ISRE binding site, where a ternary complex of promoter DNA, MUM1 and PU.1 is formed. PU.1 is a member of the Ets family and is expressed in macrophages, B cells, neutrophils and osteoclasts. 20 As shown in Figure 3c , depending on the 1st. Ets/ISRE motif, MUM1 possessed transcriptional activation activity only in the presence of PU.1. It is probably due to the fact that MUM1 binds efficiently to the Ets/ISRE motifs only in the presence of phosphorylated DNA-bound PU.1. 10 Although we did not prove that the MUM1 protein directly interacts with PU.1, we assume that they form hetero-dimers on the 5 0 MIG promoter sequences similar to complexes on Igl enhancer sequences. 5, 10 This is the first study that showed that MIG expression is upregulated by MUM1 in B cells. Previous studies have demonstrated that MIG expression is upregulated synergistically by stimulation with TNF-a and IFN-g indicating cytokine-regulated expression of inflammatory genes. 23, 24 However, in the present study, the MIG promoter was activated by TNF-a but not by IFN-g. Although we do not know the reason why our result differed from those of the previous report cannot be explained, the mechanisms activating the MIG promoter may differ according to cellular lineage and differentiation stages. At least in B cells, TNF-a seems to promote MUM1-regulated MIG induction, probably through activation of NF-kappaB signaling.
The MIG/CXCL9 gene encodes an IFN-g-inducible CXC chemokine and is expressed in activated endothelial cells and IFN-g-stimulated macrophages. 29, 30 The function of the human MIG protein is widely known as a chemotactic factor for activated T cells. 25, 29, 31 CXCR3 has been identified as the only receptor for MIG and is expressed on subsets of human peripheral T, B and NK cells. [31] [32] Recently, immunohistochemical staining showed that CXCR3 and MIG are coexpressed in distinct subtypes of B-cell lymphoma, in particular, B-CLL/SLL (CXCR3 and MIG positivity were 94.4 and 76.9%, respectively) and splenic MZL (CXCR3 and MIG positivity were 100 and 50.0%, respectively). 33 Although the expression of CXCR3 mRNA is not regulated by MUM1 as shown in our MUM1-inducible system, it is constitutively expressed on malignant B cells obtained from patients with B-CLL, whose cells show chemotaxis towards MIG. 34 Interestingly, two B-CLL cell lines expressing MUM1 also expressed MIG and CXCR3 proteins in our study. Our data suggest that MUM1 expression may be one of the mechanisms that induce MIG expression and that the MIG-CXCR3 system may constitute an autocrine loop that promotes cellular proliferation in a fraction of the B-CLL cells that express MUM1. Accordingly, this loop may be a potential therapeutic target for advanced stages of MUM1-expressing B-CLL. Finally, further identification of downstream genes whose expression is regulated by MUM1 in mature B-cell is important for considering novel therapeutic strategies, as MUM1 is frequently expressed in ABC-type DLBCL which has an unfavorable prognosis, although the vast majority of DLBCL cells do not express CXCR3. 33 
